Bortezomib-Dexamethasone, Rituximab, and Cyclophosphamide as First-Line Treatment for Waldenström's Macroglobulinemia: A Prospectively Randomized Trial of the European Consortium for Waldenström's Macroglobulinemia

Christian Buske, Meletios A. Dimopoulos, Alexander Grunenberg, Efstathios Kastritis, Cecile Tomowiak, Béatrice Mahé, Xavier Troussard, Roman Hajek, Andreas Viardot, Olivier Tournilhac, Therese Aurran, Stephane Lepretre, Hacene Zerazhi, Benedicte Hivert, Veronique Leblond, Sophie de Guibert, Lena Brandefors, Ramon Garcia-Sanz, Maria Gomes da Silva, Eva Kimby, Birgit Schmelzle, Dajana Kaszynski, Jens Dreyhaupt, Rainer Muche, Pierre Morel

Open source

DOI: 10.1200/jco.22.01805
Published: 2023-05-10
Container: Journal of Clinical Oncology
Publisher: American Society of Clinical Oncology (ASCO)
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1200/jco.22.01805,
  title = {Bortezomib-Dexamethasone, Rituximab, and Cyclophosphamide as First-Line Treatment for Waldenström's Macroglobulinemia: A Prospectively Randomized Trial of the European Consortium for Waldenström's Macroglobulinemia},
  author = {Christian Buske and Meletios A. Dimopoulos and Alexander Grunenberg and Efstathios Kastritis and Cecile Tomowiak and Béatrice Mahé and Xavier Troussard and Roman Hajek and Andreas Viardot and Olivier Tournilhac and Therese Aurran and Stephane Lepretre and Hacene Zerazhi and Benedicte Hivert and Veronique Leblond and Sophie de Guibert and Lena Brandefors and Ramon Garcia-Sanz and Maria Gomes da Silva and Eva Kimby and Birgit Schmelzle and Dajana Kaszynski and Jens Dreyhaupt and Rainer Muche and Pierre Morel},
  year = {2023},
  journal = {Journal of Clinical Oncology},
  doi = {10.1200/jco.22.01805},
  url = {https://doi.org/10.1200/jco.22.01805}
}

RIS

TY  - JOUR
TI  - Bortezomib-Dexamethasone, Rituximab, and Cyclophosphamide as First-Line Treatment for Waldenström's Macroglobulinemia: A Prospectively Randomized Trial of the European Consortium for Waldenström's Macroglobulinemia
AU  - Christian Buske
AU  - Meletios A. Dimopoulos
AU  - Alexander Grunenberg
AU  - Efstathios Kastritis
AU  - Cecile Tomowiak
AU  - Béatrice Mahé
AU  - Xavier Troussard
AU  - Roman Hajek
AU  - Andreas Viardot
AU  - Olivier Tournilhac
AU  - Therese Aurran
AU  - Stephane Lepretre
AU  - Hacene Zerazhi
AU  - Benedicte Hivert
AU  - Veronique Leblond
AU  - Sophie de Guibert
AU  - Lena Brandefors
AU  - Ramon Garcia-Sanz
AU  - Maria Gomes da Silva
AU  - Eva Kimby
AU  - Birgit Schmelzle
AU  - Dajana Kaszynski
AU  - Jens Dreyhaupt
AU  - Rainer Muche
AU  - Pierre Morel
PY  - 2023
JO  - Journal of Clinical Oncology
DO  - 10.1200/jco.22.01805
UR  - https://doi.org/10.1200/jco.22.01805
ER  -

APA

Buske, C., Dimopoulos, M. A., Grunenberg, A., Kastritis, E., Tomowiak, C., Mahé, B., Troussard, X., Hajek, R., Viardot, A., Tournilhac, O., Aurran, T., Lepretre, S., Zerazhi, H., Hivert, B., Leblond, V., Guibert, S. D., Brandefors, L., Garcia-Sanz, R., Silva, M. G. D., Kimby, E., Schmelzle, B., Kaszynski, D., Dreyhaupt, J., Muche, R., & Morel, P. (2023). Bortezomib-Dexamethasone, Rituximab, and Cyclophosphamide as First-Line Treatment for Waldenström's Macroglobulinemia: A Prospectively Randomized Trial of the European Consortium for Waldenström's Macroglobulinemia. Journal of Clinical Oncology. https://doi.org/10.1200/jco.22.01805

Source records

crossref · retrieved 2026-09-26T05:06:33.615Z